Par Health has initiated a nationwide recall of two lots of Dexmedetomidine HCl due to the discovery of cellulose particulates, posing serious health risks.

Par Health, Inc. has unveiled a ready-to-use Sugammadex Injection in prefilled syringes, enhancing healthcare workflow and patient care efficiency.

Par Health has launched the first FDA-approved generic version of Janumet® XR, enhancing access to affordable diabetes treatment in the U.S.

Par Health, a global pharmaceutical company, has appointed Norv McAndrew as its Executive Vice President and Chief Legal Officer to enhance corporate governance and compliance.

Par Health has named Dr. William Larkins as EVP and Chief Scientific Officer. His deep expertise in sterile injectables aims to drive company growth and innovation.

Par Health has successfully spun off from Mallinckrodt, establishing itself as a top U.S. player in generic drugs and sterile injectables, poised for growth.

Mallinckrodt completes the spin-off of Par Health and unveils Keenova Therapeutics, focusing on innovative therapies for unmet patient needs.

Discover the groundbreaking merger between Mallinckrodt and Endo, which aims to create a diverse global leader in therapeutics focused on addressing significant medical needs.

The merger between Mallinckrodt and Endo is set to foster a strong leadership team focused on innovative pharmaceutical advancements and patient care.